Revolution Medicines slips as investors digest recent $2.2B financing and spending outlook

Revolution Medicines (RVMD) is down 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback appears tied to financing-related dilution/overhang following the company’s recently completed large equity and convertible note offerings, alongside lingering investor sensitivity to a higher operating expense trajectory. After a sharp run-up earlier in April on pivotal pancreatic cancer trial news, some profit-taking would also be consistent with the move.

Details:

Revolution Medicines closed concurrent upsized public offerings totaling roughly $2.2 billion in gross proceeds, including common stock sold at $142.00 per share and $500 million of 0.50% convertible senior notes due 2033.

The completed equity issuance increases the share count immediately, and the convertible notes add potential future dilution if they convert, which can weigh on the stock in the days around settlement.

Earlier this month, the company disclosed positive topline Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic cancer, including a reported overall survival advantage versus chemotherapy—news that previously drove a large one-day jump, raising the risk of near-term giveback.

Separately, one analyst reduced its price target after updating forecasts for higher 2026 operating expenses following quarterly results, reinforcing the market’s focus on burn rate.

Sources:

Revolution Medicines (press release), Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 22 sales selling 320,265 shares for an estimated $33,591,043.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 5 sales selling 84,430 shares for an estimated $8,370,274.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 5 sales selling 37,450 shares for an estimated $3,578,820.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 5 sales selling 31,275 shares for an estimated $2,534,090.
JEFF CISLINI (General Counsel) has made 0 purchases and 5 sales selling 19,942 shares for an estimated $1,542,346.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 2 sales selling 9,749 shares for an estimated $846,387.
LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive RVMD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RVMD Hedge Fund Activity

We have seen 236 institutional investors add shares of $RVMD stock to their portfolio, and 141 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,482,061 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $277,346,158
WELLINGTON MANAGEMENT GROUP LLP removed 2,825,797 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $225,074,731
AVORO CAPITAL ADVISORS LLC added 2,170,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $172,840,500
JPMORGAN CHASE & CO removed 2,076,700 shares (-83.1%) from their portfolio in Q4 2025, for an estimated $165,409,155
UBS GROUP AG added 1,998,972 shares (+183.6%) to their portfolio in Q4 2025, for an estimated $159,218,119
A16Z CAPITAL MANAGEMENT, L.L.C. removed 1,827,424 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $145,554,321
LUNATE CAPITAL LTD removed 1,647,150 shares (-75.0%) from their portfolio in Q1 2026, for an estimated $160,185,337

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RVMD Analyst Ratings

Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026
Wolfe Research issued a "Outperform" rating on 11/18/2025
Wedbush issued a "Outperform" rating on 11/06/2025
Needham issued a "Buy" rating on 11/06/2025
HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
JP Morgan issued a "Overweight" rating on 11/06/2025
RBC Capital issued a "Outperform" rating on 11/03/2025

To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 15 analysts offer price targets for $RVMD in the last 6 months, with a median target of $165.0.

Here are some recent targets:

Robert Burns from HC Wainwright & Co. set a target price of $169.0 on 04/22/2026
Jonathan Chang from Leerink Partners set a target price of $171.0 on 04/22/2026
Ami Fadia from Needham set a target price of $186.0 on 04/20/2026
Laura Prendergast from Stifel set a target price of $215.0 on 04/20/2026
Robert Driscoll from Wedbush set a target price of $147.0 on 04/14/2026
Michael Schmidt from Guggenheim set a target price of $175.0 on 04/14/2026
Cory Kasimov from Evercore ISI Group set a target price of $200.0 on 04/14/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.